Company Update (NASDAQ:ILMN): Illumina, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2015


Illumina, Inc. (NASDAQ:ILMN) announced its financial results for the fourth quarter and fiscal year 2015.

Fourth quarter 2015 results:

  • Revenue of $592 million, a 15% increase compared to $512 million in the fourth quarter of 2014, and an increase of 19% on a constant currency basis
  • GAAP net income attributable to Illumina stockholders for the quarter of $104 million, or $0.70 per diluted share, compared to $153 million, or $1.03 per diluted share, for the fourth quarter of 2014
  • Non-GAAP net income attributable to Illumina stockholders for the quarter of $121 million, or $0.81 per diluted share, compared to $129 million, or $0.87 per diluted share, for the fourth quarter of 2014 (see the table entitled “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” for a reconciliation of these GAAP and non-GAAP financial measures)
  • Cash flow from operations of $240 million and free cash flow of $205 million for the quarter

Gross margin in the fourth quarter of 2015 was 69.4% compared to 75.1% in the prior year period. Excluding the effect of non-cash stock compensation expense, amortization of acquired intangible assets, legal contingencies, and impairments, non-GAAP gross margin was 71.7% for the fourth quarter of 2015 compared to 72.3% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2015 were $114.3 million compared to $142.9 million in the prior year period. R&D expenses included $10.8 million and $11.8 million of non-cash stock compensation expense in the fourth quarters of 2015 and 2014, respectively. Excluding these charges, contingent compensation, legal contingencies, and impairments, R&D expenses as a percentage of revenue were 17.5% compared to 15.7% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2015 were $147.3 million compared to $122.2 million in the prior year period. SG&A expenses included $21.4 million and $23.7 million of non-cash stock compensation expense in the fourth quarters of 2015 and 2014, respectively. Excluding these charges, amortization of acquired intangible assets, and contingent compensation, SG&A expenses as a percentage of revenue were 20.9% compared to 18.9% in the prior year period.

Depreciation and amortization expenses were $32.8 million and capital expenditures were $35.5 million during the fourth quarter of 2015. The company settled $28.6 million of the 0.25% Convertible Senior Notes due 2016 and repurchased $202.0 million of common stock under the previously announced discretionary and 10b5-1 share repurchase programs. At the close of the quarter, the company held $1.39 billion in cash, cash equivalents and short-term investments, compared to $1.34 billion as of December 28, 2014.

Fiscal 2015 results:

  • Revenue of $2,220 million, a 19% increase compared to $1,861 million in fiscal 2014, and an increase of 23% on a constant currency basis
  • GAAP net income attributable to Illumina stockholders of $462 million, or $3.10 per diluted share, compared to $353 million, or $2.37 per diluted share, in fiscal 2014
  • Non-GAAP net income attributable to Illumina stockholders of $495 million, or $3.32 per diluted share, compared to $407 million, or$2.74 per diluted share, in fiscal 2014 (see the table entitled “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” for a reconciliation of these GAAP and non-GAAP financial measures)
  • Cash flow from operations of $660 million and free cash flow of $517 million for the fiscal year

Gross margin for fiscal 2015 was 69.8% compared to 69.7% in the prior year. Excluding the effect of non-cash stock compensation expense, amortization of acquired intangible assets, legal contingencies, and impairments, non-GAAP gross margin was 72.4% for fiscal 2015 compared to 71.7% in the prior year.

Research and development (R&D) expenses for fiscal 2015 were $401.5 million compared to $388.1 million in the prior year. R&D expenses included $42.0 million and $50.9 million of non-cash stock compensation expense in fiscal 2015 and 2014, respectively. Excluding these charges, contingent compensation, legal contingencies, and impairments, R&D expenses as a percentage of revenue were 16.2% compared to 15.3% in the prior year.

Selling, general and administrative (SG&A) expenses for fiscal 2015 were $524.7 million compared to $466.3 million in the prior year. SG&A expenses included $79.1 million and $91.0 million of non-cash stock compensation expense in fiscal 2015 and 2014, respectively. Excluding these charges, amortization of acquired intangible assets, and contingent compensation, SG&A expenses as a percentage of revenue were 19.8% compared to 19.5% in the prior year.

“We closed 2015 with strong momentum as fourth quarter orders and revenue exceeded our expectations,” stated Jay Flatley, CEO. “Our recent product announcements of MiniSeq™ and Infinium® XT further enhance the most extensive genomics portfolio available. This portfolio, combined with our investments in Project Firefly, Helix, and GRAIL, will position us for long-term growth as we enable our continued penetration of the enormous markets ahead.”

Updates since our last earnings release:

  • Announced the formation of GRAIL, a new company to enable asymptomatic cancer screening through the development of a pan-cancer screening test
  • Launched the MiniSeq System, a flexible benchtop sequencer priced at $49,500, and cost-efficient to run, which will allow virtually any laboratory to adopt next-generation sequencing (NGS), regardless of sample volume
  • Launched Infinium XT, a 96-sample BeadChip offering laboratories the ability to perform genotyping on larger numbers of samples
  • Previewed Project Firefly, a highly-reliable, easy-to-use NGS platform available in the second half of 2017 that will minimize hands-on time for both library preparation and sequencing
  • Launched EpiSeq™, an NGS service for epidemiological monitoring and control of healthcare-associated infections, in partnership with bioMérieux
  • Entered into partnership with Bio-Rad Laboratories, Inc. to develop an NGS workflow for single-cell analysis
  • Entered into a collaboration with Novogene to develop clinical applications in the fields of reproductive health and oncology based on Illumina’s NGS technology

Financial outlook and guidance

The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures.

For fiscal 2016, the Company is projecting approximately 16% revenue growth, assuming current exchange rates, and non-GAAP earnings per diluted share attributable to Illumina stockholders of $3.55 to $3.65. These projections assume full year non-GAAP gross margin of approximately 73% and a net loss attributable to non-controlling interests of approximately $30 million. Full-year weighted average diluted shares outstanding, for the measurement of pro forma amounts, is expected to be approximately 149 million shares. (Original Source)

Shares of Illumina closed today at $154.66, down $4.28 or -2.69%. ILMN has a 1-year high of $242.37 and a 1-year low of $130. The stock’s 50-day moving average is $175.98 and its 200-day moving average is $181.43.

On the ratings front, Illumina has been the subject of a number of recent research reports. In a report issued on January 12, Mizuho analyst Eric Criscuolo reiterated a Hold rating on ILMN, with a price target of $150, which represents a slight downside potential from current levels. Separately, on January 11, Deutsche Bank’s Shawn Bevec maintained a Hold rating on the stock and has a price target of $178.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eric Criscuolo and Shawn Bevec have a total average return of -19.9% and 0.3% respectively. Criscuolo has a success rate of 16.7% and is ranked #3330 out of 3632 analysts, while Bevec has a success rate of 36.4% and is ranked #1977.

Overall, 3 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $175.00 which is 13.2% above where the stock opened today.

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts